Results 21 to 30 of about 105,092 (319)

H. pylori and platelet counts [PDF]

Hepatology, 2006
Abstract Helicobacter pylori (HP) eradication therapy is a useful treatment for idiopathic thrombocytopenic purpura (ITP). Some investigators have also reported the effects of proton pump inhibitor (PPI) monotherapy on ITP.
Hays L, Arnold, Stephen A, Harrison
openaire   +2 more sources

Persistence of helicobacter pylori in heterotrophic drinking-water biofilms [PDF]

, 2008
Although the route of transmission of Helicobacter pylori remains unknown, drinking water has been considered a possible transmission vector. It has been shown previously that, in water, biofilms are a protective niche for several pathogens, protecting ...
Wilks, S. A., Giao, Maria S., Wilks, Sandra A., Azevedo, N.F., Gião, M. S., Keevil, Charles W., Azevedo, N. F., Vieira, M.J., Keevil, C. W., Vieira, M. J.   +9 more
core   +1 more source

Comparison of Helicobacter pylori positive and negative gastric cancer via multi-omics analysis

mBio, 2023
Helicobacter pylori (H. pylori) has been regarded as a definite carcinogenic bacterium for gastric cancer (GC). This multi-omics research was designed to investigate the genetic, microbial, and metabolic changes of GC patients when they are infected with
Fumei Shang, Yinghao Cao, Lixin Wan, Zhonghai Ren, Xinghao Wang, Mudan Huang, Yingyun Guo   +6 more
doaj   +1 more source

Age of the association between Helicobacter pylori and man [PDF]

, 2012
When modern humans left Africa ca. 60,000 years ago (60 kya), they were already infected with Helicobacter pylori, and these bacteria have subsequently diversified in parallel with their human hosts. But how long were humans infected by H.
Linz, B., Yoshan Moodley (28753), Sebastian Suerbaum (61077), Nieuwoudt, Martin, Bond, Robert P., Moodley Yoshan, Martin Nieuwoudt (110899), Steffi Bernhöft (165529), Lawrence Mugisha, Hale James, Bodo Linz, Mugisha, L., Robert P. Bond (165515), Schalk W. van der Merwe (165547), Nieuwoudt, Martin J., van der Merwe, S., Bernhöft Steffi, Schlebusch, C., Achtman, Mark, Nieuwoudt, M., Himla Soodyall, Bodo Linz (165513), Bernhöft, S., Achtman, M., Schlebusch, Carina M., Moodley, Yoshan, Steffi Bernhöft, Bond Robert P., Linz, Bodo, Robert P Bond, Mark Achtman, Soodyall Himla, Suerbaum, S., Mugisha, Lawrence, Mugisha Lawrence, James Hale, Carina M. Schlebusch (165523), van der Merwe Schalk W., Schalk W van der Merwe, Soodyall, Himla, Martin Nieuwoudt, Hale, James, Sebastian Suerbaum, Carina M Schlebusch, Mark Achtman (126786), Suerbaum Sebastian, Achtman Mark, Himla Soodyall (165519), Bond, R., Soodyall, H., Suerbaum, Sebastian, Van der Merwe, Schalk Willem, Linz Bodo, Nieuwoudt Martin, Moodley, Y., James Hale (165534), Hale, J., Schlebusch Carina M., Van der Merwe, Schalk W., Bernhöft, Steffi, Hale, J. (James), Yoshan Moodley, Lawrence Mugisha (165542)   +62 more
core   +1 more source

The sodium-dependent D-glucose transport protein of Helicobacter pylori [PDF]

, 2008
Helicobacter pylori is a gram-negative pathogenic microaerophile with a particular tropism for the mucosal surface of the gastric epithelium. Despite its obligatory microaerophilic character, it can metabolize D-glucose and/or D-galactose in both ...
Kim E. Bettaney, Polaczek, Julia, Lars‐Oliver Essen, Massoud Saidijam, Hope, Ryan, Shibayama, Keigo, Henderson, Peter J.F., Saidijam, Massoud, Jocelyn M. Baldwin, Stephen A. Baldwin, Essen, Lars-Oliver, Psakis, Georgios, Baldwin, Jocelyn M., Bettaney, Kim E., Peter J. F. Henderson, Baldwin, Stephen A., Ryan Hope, Julia Polaczek, Richard C. Essenberg, Georgios Psakis, Keigo Shibayama, Essenberg, Richard C.   +21 more
core   +1 more source

Mixed infection with cagA positive and cagA negative strains of Helicobacter pylori lowers disease burden in The Gambia. [PDF]

, 2011
BACKGROUND: The prevalence of Helicobacter pylori including strains with putatively virulent genotypes is high, whereas the H. pylori-associated disease burden is low, in Africa compared to developed countries.
Douglas E. Berg, Martin Antonio, Walton, Robert T., Mary Tapgun, Thomas Vivat, Thomas Julian E., Walton, R, Thomas, Vivat, Julian E Thomas, Tapgun, M., Corrah, T, Thomas, JE, Christian Bottomley, Tumani Corrah, Berg, D. E., Corrah, Tumani, Douglas E Berg, Adegbola, Richard A, Tapgun, M, Corrah Tumani, Bottomley, C, Robert Walton, Thomas, J., Corrah, T., Adegbola, R. A., Bottomley, C., Thomas, V., Antonio, M, Berg, Douglas E, Walton Robert, Richard A. Adegbola, Vivat Thomas, Secka, Ousman, Berg Douglas E., Richard A Adegbola, Bottomley, Christian, Ousman Secka, Tapgun, Mary, Secka, O, Tapgun Mary, Secka Ousman, Berg, DE, Julian E. Thomas, Secka, O., Thomas, Julian E, Walton, Robert, Antonio Martin, Thomas, V, Adegbola Richard A., Bottomley Christian, Adegbola, RA, Antonio, Martin   +51 more
core   +1 more source

A change of IL-2 and IL-4 production in patients with Helicobactor pylori infection

Mediators of Inflammation, 1995
Helicobactor pylori is the most common cause of gastroduodenal inflammation. However, the exact immune pathogenesis is not fully understood. To look for evidence of the immunological mechanism in H.
X. G. Fan, J. Yakoob, X. J. Fan, P. W. N. Keeling   +3 more
doaj   +1 more source

Prevalence of Helicobacter pylori infection in dyspeptic patients in Iran

Gastroenterology Insights, 2012
Although Helicobacter pylori (H. pylori) infection has been known to be associated with several upper gastrointestinal disorders such as peptic ulcer and gastric cancer, the relationship between H.
Leila Shokrzadeh, Kaveh Baghaei, Yoshio Yamaoka, Seiji Shiota, Dariush Mirsattari, Asma Porhoseingholi, Mohammad Reza Zali   +6 more
doaj   +1 more source

Helicobacter pylori and Other Gastrointestinal Diseases [PDF]

The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2020
Helicobacter pylori (H. pylori) is the most prevalent bacterial pathogen that infects approximately half of the world’s population. It is well known that H. pylori causes chronic gastritis, peptic ulcer, and gastric cancer. H.
Jong Kyu Park
doaj   +1 more source

H. pyloriEradication Therapy [PDF]

Gastroenterology Research and Practice, 2013
As a general rule for the treatment of infectious diseases, clinicians should prescribe anti-H. pylori regimens that have a per-protocol eradication rate ≥90%. However, the eradication rate of the standard triple therapy recommended by most guidelines has generally declined to unacceptable levels (i.e., 80% or less) recently.
Ping-I Hsu, Nan-Jing Peng
openaire   +3 more sources